Penumbra director Arani sells $3.45 million in stock By Investing.com Penumbra director Arani sells $3.45 million in stock…
Penumbra im Pivotal-Point-Check: Innovativer Medizintechnikhersteller überzeugt mit starkem Thrombektomiegeschäft - UBS mit Kaufempfehlung nach Q4-Zahlen! Das US-Thrombektomiegeschäft verzeichnete im 4. Quartal mit einem Anstieg von 27,3 % im Vergleich zum Vorjahr ein deutliches Wachstum.…
Penumbra überzeugt mit Marktanteilsgewinnen bei computergestützter Thrombektomie - Aktie mit neuem Jahreshoch! Penumbra (PEN) hat sich als Medizintechnikunternehmen auf die minimalinvasive Behandlung von neurovaskulären und peripheren Gefäßerkrankungen spezialisiert. Der US-Markt ist für…
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.…
Heres What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but…
Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains? Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend…
Penumbra stock rises following Strykers Inari Medical acquisition By Investing.com Penumbra stock rises following Strykers Inari Medical acquisition…
Is Penumbra Stock a Smart Buy for Your Portfolio Right Now? PEN stays on investors radars due to its robust portfolio expansion and international growth plans.…
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market The third-quarter results reflect another strong performance by Penumbras U.S. thrombectomy business.…
Why Penumbra Stock Zoomed 4% Higher Today The latest news from the lab, plus an analysts bullish move, combined to put some zip in the companys shares.…
Why Penumbra Stock Zoomed Nearly 5% Higher Today The company might just be the right kind of business operating at the right time in history.…
PEN Stock to Gain From CE Mark Approval for its CAVT Technologies Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.…
Penumbra (PEN) Soars 3.3%: Is Further Upside Left in the Stock? Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend…
Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand Penumbras (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.…
Penumbras (PEN) New Launch to Enhance Blood Clot Removal Penumbras (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.…
Penumbra (PEN) Gains From Innovation, Mounting Costs Ail Penumbra (PEN) expects to materially increase both revenues and profitability in the companys international business in the next three years…